Interleukin-2 synthesis pathway

The **Interleukin‑2 synthesis pathway** refers to the complex cellular processes that regulate production and secretion of interleukin‑2 (IL‑2), a key cytokine in immune system function. This is *not* a single molecular target but rather an interconnected network involving T cell activation through antigen recognition by T cell receptors, costimulatory signals such as CD28 engagement, and downstream intracellular signaling cascades including PLC-dependent pathways that activate transcription factors like NFAT, NFκB, and AP‑1. These events culminate in transcriptional upregulation and secretion of IL‑2 by activated T cells. The secreted IL‑2 then acts in an autocrine/paracrine manner via binding to its heterotrimeric receptor on various immune cells—primarily supporting proliferation and differentiation of effector T cells as well as regulatory T cells. Dysregulation or therapeutic manipulation of this axis is relevant in cancer immunotherapy, autoimmune diseases, infection control, and transplant medicine. **Note:** This entry is considered incorrect as a therapeutic target because “Interleukin–2 synthesis pathway” describes an entire biological process rather than a discrete druggable entity such as a protein/receptor/enzyme. Drugs typically target specific molecules within this process—most notably interleukin–2 itself or components of its receptor complex—not the overall “pathway.” For structured data purposes it should be mapped instead to either “Interleukin–2” or “Interleukin–2 receptor,” depending on context.

Other names

IL-2 synthesis pathwayInterleukin 2 signaling pathwayIL2 signaling cascade